Journal
CANCER AND METASTASIS REVIEWS
Volume 30, Issue 2, Pages 253-268Publisher
SPRINGER
DOI: 10.1007/s10555-011-9288-x
Keywords
Heparanase; Hpa2; Cathepsin L; Metastasis; Tumor microenvironment; Urofacial syndrome
Categories
Funding
- Israel Science Foundation [593/10]
- National Cancer Institute, NIH [RO1-CA106456]
- Israel Cancer Research Fund (ICRF)
- Ministry of Science and Technology of the State of Israel
- German Cancer Research Center (DKFZ)
Ask authors/readers for more resources
Tumor metastasis, the leading cause of cancer patients' death, is still insufficiently understood. While concepts and mechanisms of tumor metastasis are evolving, it is widely accepted that cancer metastasis is accompanied by orchestrated proteolytic activity executed by array of proteases. While matrix metalloproteinases (MMPs) attracted much attention, other proteases constitute the tumor milieu, of which a large family consists of cysteine proteases named cathepsins. Like MMPs, some cathepsins are often upregulated in cancer and, once secreted or localized to the cell surface, can degrade components of the extracellular matrix. In addition, cathepsin L is held responsible for processing and activation of heparanase, an endo-beta-glucuronidase capable of cleaving heparan sulfate side chains of heparan sulfate proteoglycans, activity that is strongly implicated in cell dissemination associated with tumor metastasis, angiogenesis, and inflammation. In this review, we discuss recent progress in heparanase research focusing on heparanase-related molecules namely, cathepsin L and heparanase 2 (Hpa2), a heparanase homolog.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available